Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Significance: Although PD-1 blockade has innovated cancer therapy, a novel combinatorial strategy is required to save less sensitive cancer patients. Mitochondria are key cytoplasmic organelles that efficiently supply the ATP necessary for the rapid proliferation and differentiation of T cells. We found that reactive oxygen species (ROS) strongly activate mitochondrial function of tumor-reactive T cells and synergize tumor regression by PD-1 blockade. ROS appear to activate both AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR), which subsequently induce the PPAR-gamma coactivator 1α (PGC-1α) transcription factor. Small-molecule activators of AMPK and mTOR, or PGC-1α, also synergistically enhance tumor-growth suppression by PD-1 blockade therapy. These findings not only open a new aspect of immune metabolism but also pave a way to developing a combinational strategy of PD-1 cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“It is also a mystery how effective immune surveillance induced by PD-1 blockade can last for years in treated cancer patients (15, 16).”
BackgroundTopHat: discovering splice junctions with RNA-Seq
Trapnell, C., Pachter, L., & Salzberg, S. L. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp120 · Cited by 11,617
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“It is also a mystery how effective immune surveillance induced by PD-1 blockade can last for years in treated cancer patients (15, 16).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 2×
“One problem with studying the mechanism of PD-1 blockade therapy is the difficulty in identification of the TR CTLs, because PD-1 blockade likely generates CTLs with a large repertoire of TCRs in response to a variety of tumor antigens (22, 23).”
BackgroundNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“However, around 30 to 50% of patients still remain unresponsive, or less responsive, to PD-1 blockade therapy (5, 6).”
BackgroundTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“Because exogenous ROS or its generators are known to directly damage tumor cells (27), we first tested whether a ROS generator alone exhibits tumor-killing activity.”
BackgroundMitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Self-citationClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citationZou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Self-citationmTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Sena, L. A., Li, S., Jairaman, A., Prakriya, M., Ezponda, T., Hildeman, D. A., Wang, C.-R., Schumacker, P. T., Licht, J. D., Perlman, H., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.020 · Cited by 1,338 · cited 1×
“Recently, mitochondrial activation has been reported to be critical for generation of T-cell proliferation and memory formation by studies in vitro (17) as well as in vivo (18).”
BackgroundCombination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · cited 2×
“Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8(7):579–591.”
BackgroundT cell metabolism drives immunity
Buck, M. D., O’Sullivan, D., & Pearce, E. L. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151159 · Cited by 1,179
AMP-activated protein kinase mediates mitochondrial fission in response to energy stress
Toyama, E. Q., Herzig, S., Courchet, J., Lewis, T. L., Losón, O. C., Hellberg, K., Young, N. P., Chen, H., Polleux, F., Chan, D. C., et al. (2016) · Science · doi:10.1126/science.aab4138 · Cited by 1,085 · cited 1×
“Mitochondrial energy metabolism is closely linked with cellular metabolism via mTOR and AMPK (36, 49, 50).”
BackgroundRegulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035 · cited 1×
“Mitochondrial energy metabolism is closely linked with cellular metabolism via mTOR and AMPK (36, 49, 50).”
BackgroundMitochondria in the Regulation of Innate and Adaptive Immunity
Weinberg, S. E., Sena, L. A., & Chandel, N. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.002 · Cited by 960
Transcriptional control of mitochondrial biogenesis: the central role of PGC-1
Ventura-Clapier, R., Garnier, A., & Veksler, V. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn098 · Cited by 932 · cited 3×
“The reduction of PGC-1α mRNA by PD-L1 mAb treatment alone despite an increase in its protein is probably due to multiple steps of PGC-1α regulation, namely transcription, translation, and protein stabilization (44, 45).”
BackgroundOkazaki, T., Chikuma, S., Iwai, Y., Fagarasan, S., & Honjo, T. (2013) · Nature Immunology · doi:10.1038/ni.2762 · Cited by 916
Self-citationProgenitor and Terminal Subsets of CD8 + T Cells Cooperate to Contain Chronic Viral Infection
Paley, M. A., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett, B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., et al. (2012) · Science · doi:10.1126/science.1229620 · Cited by 902
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848 · cited 1×
“Two papers very recently published, showing that PD-1 signal blocks mitochondrial activity and PGC-1α expression, strongly support our hypothesis (55, 56).”
ResultOkazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Self-citationAMPK and mTOR in Cellular Energy Homeostasis and Drug Targets
Inoki, K., Kim, J., & Guan, K.-L. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134537 · Cited by 791
Uncoupling to survive? The role of mitochondrial inefficiency in ageing
Brand, M. D. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00135-2 · Cited by 789 · cited 1×
“Although chemical uncouplers are known to decrease ROS production in isolated mitochondria (30, 31), there are reports that the uncouplers rather increase mitochondrial ROS production in cells through hypoxia and HIF-1α activity (32–34).”
BackgroundScharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 706
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., et al. (2003) · Nature Medicine · doi:10.1038/nm955 · Cited by 689
Self-citationThe Energy Sensor AMPK Regulates T Cell Metabolic Adaptation and Effector Responses In Vivo
Blagih, J., Coulombe, F., Vincent, E. E., Dupuy, F., Galicia-Vázquez, G., Yurchenko, E., Raissi, T. C., van der Windt, G. J. W., Viollet, B., Pearce, E. L., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.030 · Cited by 664
The mitochondrial uncoupling-protein homologues
Krauss, S., Zhang, C.-Y., & Lowell, B. B. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1592 · Cited by 663
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552 · cited 1×
“Although preexisting TILs were previously reported to be sufficient for B16 regression in a case of CTLA-4 and PD-1 doubleblocking immunotherapy, the reported system differs from ours in the therapy mAb and timing and route of FTY720 administration (57).”
ResultmTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552 · cited 1×
“PGC-1α, a transcriptional cofactor regulated by either AMPK or mTOR, is known to enhance mitochondrial biogenesis and oxidative phosphorylation (43, 44).”
BackgroundCD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability
van der Windt, G. J. W., O’Sullivan, D., Everts, B., Huang, S. C.-C., Buck, M. D., Curtis, J. D., Chang, C.-H., Smith, A. M., Ai, T., Faubert, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221740110 · Cited by 523
Nishimura, H. (1998) · International Immunology · doi:10.1093/intimm/10.10.1563 · Cited by 500
PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver
Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., & Honjo, T. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022235 · Cited by 392
Self-citationStaron, M. M., Gray, S. M., Marshall, H. D., Parish, I. A., Chen, J. H., Perry, C. J., Cui, G., Li, M. O., & Kaech, S. M. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.013 · Cited by 385
Linear Differentiation of Cytotoxic Effectors into Memory T Lymphocytes
Opferman, J. T., Ober, B. T., & Ashton-Rickardt, P. G. (1999) · Science · doi:10.1126/science.283.5408.1745 · Cited by 380
T cell metabolic fitness in antitumor immunity
Siska, P. J., & Rathmell, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.007 · Cited by 312
Rao, R. R., Li, Q., Bupp, M. R. G., & Shrikant, P. A. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.015 · Cited by 293
Li, J., Jie, H.-B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., Kane, L. P., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 246
Metabolism, migration and memory in cytotoxic T cells
Finlay, D., & Cantrell, D. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2888 · Cited by 225
A fundamental system of cellular energy homeostasis regulated by PGC-1α
Rohas, L. M., St-Pierre, J., Uldry, M., Jäger, S., Handschin, C., & Spiegelman, B. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702683104 · Cited by 208
Mitochondrial function provides instructive signals for activation-induced B-cell fates
Jang, K.-J., Mano, H., Aoki, K., Hayashi, T., Muto, A., Nambu, Y., Takahashi, K., Itoh, K., Taketani, S., Nutt, S. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms7750 · Cited by 194
Measuring Bioenergetics in T Cells Using a Seahorse Extracellular Flux Analyzer
van der Windt, G. J. W., Chang, C., & Pearce, E. L. (2016) · Current Protocols in Immunology · doi:10.1002/0471142735.im0316bs113 · Cited by 193
Friederich-Persson, M., Thörn, E., Hansell, P., Nangaku, M., Levin, M., & Palm, F. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01425 · Cited by 176
Yu, Z., Shao, W., Chiang, Y., Foltz, W., Zhang, Z., Ling, W., Fantus, I. G., & Jin, T. (2011) · Diabetologia · doi:10.1007/s00125-010-2001-8 · Cited by 173
Real-time tracking of cell cycle progression during CD8+ effector and memory T-cell differentiation
Kinjyo, I., Qin, J., Tan, S.-Y., Wellard, C. J., Mrass, P., Ritchie, W., Doi, A., Cavanagh, L. L., Tomura, M., Sakaue-Sawano, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7301 · Cited by 149
Sano, M., Tokudome, S., Shimizu, N., Yoshikawa, N., Ogawa, C., Shirakawa, K., Endo, J., Katayama, T., Yuasa, S., Ieda, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703634200 · Cited by 114
Dixit, D., Ghildiyal, R., Anto, N. P., & Sen, E. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.179 · Cited by 108
Tenenbaum, A., & Fisman, E. Z. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-140 · Cited by 107
Kimball, S. R., Do, A. N. D., Kutzler, L., Cavener, D. R., & Jefferson, L. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706643200 · Cited by 106
Gloerich, J., van Vlies, N., Jansen, G. A., Denis, S., Ruiter, J. P. N., van Werkhoven, M. A., Duran, M., Vaz, F. M., Wanders, R. J. A., & Ferdinandusse, S. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400337-jlr200 · Cited by 80
Pharmacophore modeling and parallel screening for PPAR ligands
Markt, P., Schuster, D., Kirchmair, J., Laggner, C., & Langer, T. (2007) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-007-9140-0 · Cited by 74
Han, Y. H., Kim, S. H., Kim, S. Z., & Park, W. H. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.05.005 · Cited by 74
Uzhachenko, R. V., Shanker, A., Yarbrough, W. G., & Ivanova, A. V. (2015) · Oncotarget · doi:10.18632/oncotarget.4537 · Cited by 43
Berrien-Elliott, M. M., Yuan, J., Swier, L. E., Jackson, S. R., Chen, C. L., Donlin, M. J., & Teague, R. M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0159 · Cited by 42
AMPK : A metabolic switch for CD 8+ T ‐cell memory
Araki, K., & Ahmed, R. (2013) · European Journal of Immunology · doi:10.1002/eji.201343483 · Cited by 30
Free radicals run in lizard families without (and perhaps with) mitochondrial uncoupling
Olsson, M. M., Wilson, M. R., Uller, T., & Isaksson, C. (2009) · Biology Letters · doi:10.1098/rsbl.2009.0115 · Cited by 5
Cited by
Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654
“Interestingly, enhanced mitochondrial activity and ROS production synergize with the tumoricidal activity of PD-1 blockade by expansion of effector/memory T cells (Chamoto et al., 2017).”
BackgroundThe diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Clonal replacement of tumor-specific T cells following PD-1 blockade
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360
“Anti-tumor T cell function induced by PD-1 blockade in mice could also be improved by a targeted increase in mitochondrial function (120).”
Background
Metadata
- Authors
- Chamoto, K., Chowdhury, P. S., Kumar, A., Sonomura, K., Matsuda, F., Fagarasan, S., & Honjo, T.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2017-01-17
- Volume
- 114
- Issue
- 5
- Pages
- E761-E770
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2573158190
- Cited by
- 413
- References
- 63
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.